Research progress on mechanisms of PD-1 inhibitor resistance in the treatment of gastric cancer
10.12354/j.issn.1000-8179.2025.20241631
- VernacularTitle:PD-1抑制剂治疗胃癌耐药机制的研究进展
- Author:
Xu JIANJIANG
1
;
Liu TAO
;
Jiang LEI
Author Information
1. 兰州大学第一临床医学院(兰州市 730000)
- Publication Type:Journal Article
- Keywords:
gastric cancer(GC);
programmed cell death protein-1(PD-1)inhibitors;
immunotherapy;
drug resistance
- From:
Chinese Journal of Clinical Oncology
2025;52(4):188-192
- CountryChina
- Language:Chinese
-
Abstract:
Gastric cancer(GC)is one of the most prevalent malignant tumors worldwide.Although the incidence of GC has significantly de-creased over the past decade owing to advancements in early stage diagnostic techniques,its mortality rate remains high.Immune check-point inhibitors(ICIs),such as programmed cell death protein-1(PD-1)inhibitors,have become a promising treatment option for patients with GC.However,only a minority of patients with GC exhibit durable responses to PD-1 inhibitor therapy.Moreover,the overall efficacy of these treatments is limited.Existing studies have indicated that immunotherapeutic failure is closely associated with the development of res-istance to PD-1 inhibitors;however,the mechanisms underlying this resistance are not fully understood.Therefore,this review aimed to ex-plore the potential molecular mechanisms contributing to the resistance to PD-1 inhibitors in the treatment of GC and provide a new re-search perspective on the clinical responses to this resistance.
